Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M94.9Revenue (TTM) $M--Net Margin (%)--Altman Z-Score-1.7
Enterprise Value $M23.3EPS (TTM) $-3.5Operating Margin %--Piotroski F-Score2
P/E(ttm)--Beneish M-Score-3.7Pre-tax Margin (%)--Higher ROA y-yN
Price/Book1.110-y EBITDA Growth Rate %--Quick Ratio9.9Cash flow > EarningsY
Price/Sales--5-y EBITDA Growth Rate %-4.5Current Ratio9.9Lower Leverage y-yY
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)-58.7Higher Current Ratio y-yN
Dividend Yield %--PEG--ROE % (ttm)-68.8Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M22.6ROIC % (ttm)-258.9Gross Margin Increase y-yN

Gurus Latest Trades with CASC

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
CASCSeth Klarman 2016-06-30 Buy 0.32%$5.1 - $8.1
($6.8)
$ 4.21-38%New holding4,166,675
CASCFirst Eagle Investment 2016-06-30 Buy $5.1 - $8.1
($6.8)
$ 4.21-38%New holding66,667
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

CASC is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!


CASC: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Myers Scott DunsethPresident and CEO 2016-08-17Buy7,500$6.9-38.84view
Myers Scott DunsethPresident and CEO 2016-06-28Buy10,417$4.8-12.08view
HAUSMAN DIANAChief Medical Officer 2015-06-01Buy5,747$4.65-9.25view
SPIEGELMAN DANIEL KDirector 2015-03-26Buy20,000$1.61162.11view
SPIEGELMAN DANIEL KDirector 2015-03-26Buy20,000$1.61162.11view
BVF PARTNERS L P/IL10% Owner 2014-12-12Sell0$0162.11view
Venkatesan JayEVP and General Manager 2014-09-23Buy250,000$2111view
BVF PARTNERS L P/IL10% Owner 2013-11-01Buy129,000$1.78137.08view
BVF PARTNERS L P/IL10% Owner 2013-08-08Buy258,361$1.65155.76view
BVF PARTNERS L P/IL10% Owner 2013-08-01Buy338,087$1.74142.53view

Quarterly/Annual Reports about CASC:

    News about CASC:

    Articles On GuruFocus.com
    Seth Klarman Buys 25 Million Shares of Cascadian Therapeutics as Price Declines Jul 12 2016 
    Seth Klarman Buys 25 Million Shares of Cascadian Therapeutics Jul 11 2016 
    Value Betting with Special Situations: Lessons from the World of Gambling Mar 05 2013 
    Cubist Pharmaceutical - Acutely Aware May 09 2010 

    More From Other Websites
    Cascadian Therapeutics Announces 2017 Outlook and Recent Drug Portfolio Progress Jan 05 2017
    Cascadian Therapeutics Announces 2017 Outlook and Recent Drug Portfolio Progress Jan 05 2017
    Cascadian Therapeutics Appoints Dr. Marc L. Lesnick as Senior Vice President, Regulatory Affairs and... Jan 04 2017
    Cascadian Therapeutics Appoints Dr. Marc L. Lesnick as Senior Vice President, Regulatory Affairs and... Jan 04 2017
    Should You Buy Alico, Inc. (ALCO)? Dec 20 2016
    Here’s What Smart Money Think about Jones Energy Inc (JONE) Dec 12 2016
    Do Hedge Funds Love Invuity, Inc. (IVTY)? Dec 10 2016
    Biotech Movers And Shakers: Cascadian Therapeutics Inc (USA) (CASC) And Anthera Pharmaceuticals Inc... Dec 08 2016
    CASCADIAN THERAPEUTICS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits Dec 07 2016
    Cascadian Therapeutics Amends HER2CLIMB Phase 2 Trial of Tucatinib in Metastatic HER2-Positive... Dec 07 2016
    Cascadian Therapeutics Enlarges Breast Cancer Pill Study to Meet FDA Registration Standards Dec 07 2016
    Cascadian Therapeutics, Inc. :CASC-US: Earnings Analysis: Q3, 2016 By the Numbers : December 1, 2016 Dec 01 2016
    Cascadian Therapeutics Strengthens Management Team with Key Hires, Monique M. Greer and Marc C.... Nov 28 2016
    Cascadian Therapeutics Announces Stockholders and Board of Directors Approve Reverse Stock Split Nov 23 2016
    CASCADIAN THERAPEUTICS, INC. Files SEC form 8-K, Amendments to Articles of Inc. or Bylaws; Change in... Nov 23 2016
    Cascadian Therapeutics Announces Stockholders and Board of Directors Approve Reverse Stock Split Nov 23 2016
    CASCADIAN THERAPEUTICS, INC. Financials Nov 16 2016
    Cascadian Therapeutics Announces Presentations of Updated Clinical Data at the 2016 San Antonio... Nov 15 2016
    CASCADIAN THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition,... Nov 07 2016
    Cascadian Therapeutics Reports Third Quarter 2016 Financial Results and Provides Corporate Update Nov 07 2016

    Add Notes, Comments

    If you want to ask a question or report a bug, please create a support ticket.
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)